Sanofi-Aventis, the biggest player on Romania's pharmaceutical market, which owns Zentiva producer, is set to start exporting ten drugs produced in the plant it owns in Bucharest in February-March 2011.
Delivers to foreign markets will go to countries such as France, Germany, Italy, United Kingdom, Portugal. At present, the company has a small presence abroad, in the Republic of Moldova, but higher export volumes will be reached with the ten products aimed at Western markets.
The drugs will be from areas such as urology and hypertension, as well as others. Dan Ivan, country head with Sanofi-Aventis and chairman of Zentiva SA board, explained the Bucharest plant has several advantages.
"The production capacity, of above 2 billion tablets, is not 100% used," Dan Ivan said.
The company's representatives did not provide any data on the estimated value of exports or their weight in the plant's annual production.
Sanofi-Aventis, the biggest player on Romania's pharmaceutical market, which owns Zentiva producer, is set to start exporting ten drugs produced in the plant it owns in Bucharest in February-March 2011.
Delivers to foreign markets will go to countries such as France, Germany, Italy, United Kingdom, Portugal. At present, the company has a small presence abroad, in the Republic of Moldova, but higher export volumes will be reached with the ten products aimed at Western markets.
The drugs will be from areas such as urology and hypertension, as well as others. Dan Ivan, country head with Sanofi-Aventis and chairman of Zentiva SA board, explained the Bucharest plant has several advantages.
"The production capacity, of above 2 billion tablets, is not 100% used," Dan Ivan said.
The company's representatives did not provide any data on the estimated value of exports or their weight in the plant's annual p